Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
← catalyst calendarSponsored by Celyad Oncology SA (industry) · CYAD.BR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
27estimated
Sites
5
Countries
Belgium, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-11-25 | actual | When the study began enrolling |
| Primary completion | Dec 2021 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2020-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
- Biological: CYAD-02
- Drug: ENDOXAN — also filed as cyclophosphamide
- Drug: Fludara — also filed as fludarabine
Primary outcome
what the primary-completion date above is the date OFOccurrence of Dose Limiting Toxicities as defined per protocol in order to define the final recommended dose.
measured from start the first infusion of CYAD-02 (Day1) up to Day36.
Permalink · CYAD.BR's whole pipeline · Catalyst calendar · Every registered study · What changed